77 related articles for article (PubMed ID: 34009286)
21. SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations.
Yang WT; Huang WH; Liao TL; Hsiao TH; Chuang HN; Liu PY
Infect Drug Resist; 2022; 15():373-385. PubMed ID: 35140483
[TBL] [Abstract][Full Text] [Related]
22. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants.
Weigang S; Fuchs J; Zimmer G; Schnepf D; Kern L; Beer J; Luxenburger H; Ankerhold J; Falcone V; Kemming J; Hofmann M; Thimme R; Neumann-Haefelin C; Ulferts S; Grosse R; Hornuss D; Tanriver Y; Rieg S; Wagner D; Huzly D; Schwemmle M; Panning M; Kochs G
Nat Commun; 2021 Nov; 12(1):6405. PubMed ID: 34737266
[TBL] [Abstract][Full Text] [Related]
23. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
24. Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.
Li T; Han X; Gu C; Guo H; Zhang H; Wang Y; Hu C; Wang K; Liu F; Luo F; Zhang Y; Hu J; Wang W; Li S; Hao Y; Shen M; Huang J; Long Y; Song S; Wu R; Mu S; Chen Q; Gao F; Wang J; Long S; Li L; Wu Y; Gao Y; Xu W; Cai X; Qu D; Zhang Z; Zhang H; Li N; Gao Q; Zhang G; He C; Wang W; Ji X; Tang N; Yuan Z; Xie Y; Yang H; Zhang B; Huang A; Jin A
Nat Commun; 2021 Nov; 12(1):6304. PubMed ID: 34728625
[TBL] [Abstract][Full Text] [Related]
25. Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants.
Upadhyay V; Lucas A; Panja S; Miyauchi R; Mallela KMG
J Biol Chem; 2021 Oct; 297(4):101208. PubMed ID: 34543625
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
[TBL] [Abstract][Full Text] [Related]
27. Emergence of SARS-CoV-2 Variant B.1.575.2, Containing the E484K Mutation in the Spike Protein, in Pamplona, Spain, May to June 2021.
Trobajo-Sanmartín C; Miqueleiz A; Portillo ME; Fernández-Huerta M; Navascués A; Sola Sara P; López Moreno P; Ordoñez GR; Castilla J; Ezpeleta C
J Clin Microbiol; 2021 Nov; 59(12):e0173621. PubMed ID: 34495709
[TBL] [Abstract][Full Text] [Related]
28. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
Front Immunol; 2021; 12():715464. PubMed ID: 34539645
[TBL] [Abstract][Full Text] [Related]
29. In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron.
Hu YF; Hu JC; Chu H; Yau T; Zhang BZ; Huang JD
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215983
[TBL] [Abstract][Full Text] [Related]
30. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany.
Jensen B; Luebke N; Feldt T; Keitel V; Brandenburger T; Kindgen-Milles D; Lutterbeck M; Freise NF; Schoeler D; Haas R; Dilthey A; Adams O; Walker A; Timm J; Luedde T
Lancet Reg Health Eur; 2021 Sep; 8():100164. PubMed ID: 34278371
[TBL] [Abstract][Full Text] [Related]
31. Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants.
Laffeber C; de Koning K; Kanaar R; Lebbink JHG
J Mol Biol; 2021 Jul; 433(15):167058. PubMed ID: 34023401
[TBL] [Abstract][Full Text] [Related]
32. Letter to the Editor: Characteristics of Liver Transplant Patients Admitted with COVID-19.
Mansoor E; Sclair SS; Cooper GS
Gastroenterology; 2021 Sep; 161(3):1069-1070. PubMed ID: 34015338
[No Abstract] [Full Text] [Related]
33. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.
Peiffer-Smadja N; Bridier-Nahmias A; Ferré VM; Charpentier C; Garé M; Rioux C; Allemand A; Lavallée P; Ghosn J; Kramer L; Descamps D; Yazdanpanah Y; Visseaux B
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452507
[TBL] [Abstract][Full Text] [Related]
34. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
Cohen MS; Nirula A; Mulligan MJ; Novak RM; Marovich M; Yen C; Stemer A; Mayer SM; Wohl D; Brengle B; Montague BT; Frank I; McCulloh RJ; Fichtenbaum CJ; Lipson B; Gabra N; Ramirez JA; Thai C; Chege W; Gomez Lorenzo MM; Sista N; Farrior J; Clement ME; Brown ER; Custer KL; Van Naarden J; Adams AC; Schade AE; Dabora MC; Knorr J; Price KL; Sabo J; Tuttle JL; Klekotka P; Shen L; Skovronsky DM;
JAMA; 2021 Jul; 326(1):46-55. PubMed ID: 34081073
[TBL] [Abstract][Full Text] [Related]
35. Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies.
Pommeret F; Colomba J; Bigenwald C; Laparra A; Bockel S; Bayle A; Michot JM; Hueso T; Albiges L; Tiberghien P; Marot S; Jary A; Lacombe K; Barlesi F; Griscelli F; Colomba E
Ann Oncol; 2021 Nov; 32(11):1445-1447. PubMed ID: 34352377
[No Abstract] [Full Text] [Related]
36. Bamlanivimab for Prevention of COVID-19.
Kuritzkes DR
JAMA; 2021 Jul; 326(1):31-32. PubMed ID: 34081075
[No Abstract] [Full Text] [Related]
37. Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients.
Kutzler HL; Kuzaro HA; Serrano OK; Feingold A; Morgan G; Cheema F
Transpl Infect Dis; 2021 Oct; 23(5):e13662. PubMed ID: 34081820
[TBL] [Abstract][Full Text] [Related]
38. Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19.
Ganesh R; Pawlowski C; O'Horo JC; Arndt LL; Arndt R; Bell SJ; Bierle DM; Borgen MD; Hanson SN; Heyliger A; Larsen JJ; Lenehan P; Orenstein R; Puranik A; Speicher LL; Tulledge-Scheitel SM; Venkatakrishnan AJ; Wilker CG; Badley AD; Razonable RR
medRxiv; 2021 May; ():. PubMed ID: 34075387
[TBL] [Abstract][Full Text] [Related]
39. Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19.
Bierle DM; Ganesh R; Wilker CG; Hanson SN; Moehnke DE; Jackson TA; Ramar P; Rosedahl JK; Philpot LM; Razonable RR
J Prim Care Community Health; 2021; 12():21501327211019282. PubMed ID: 34032171
[TBL] [Abstract][Full Text] [Related]
40. Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance.
Guigon A; Faure E; Lemaire C; Chopin MC; Tinez C; Assaf A; Lazrek M; Hober D; Bocket L; Engelmann I; Alidjinou EK
J Infect; 2022 Feb; 84(2):248-288. PubMed ID: 34437928
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
